Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AVTX

Avalo Therapeutics Inc

Dec 08 • 04:00PM ET

0.0530

Dollar change -0.0076
Percentage change -12.54	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.59	Insider Own	0.12%	Shs Outstand	192.38M	Perf Week	-18.59%
Market Cap	10.20M	Forward P/E	-	EPS next Y	-0.07	Insider Trans	-94.04%	Shs Float	192.15M	Perf Month	-51.38%
Income	-33.19M	PEG	-	EPS next Q	-0.02	Inst Own	0.70%	Short Float / Ratio	9.44% / 0.24	Perf Quarter	-37.57%
Sales	2.25M	P/S	4.53	EPS this Y	90.97%	Inst Trans	-0.18%	Short Interest	18.14M	Perf Half Y	-98.68%
Book/sh	0.08	P/B	0.69	EPS next Y	82.50%	ROA	-100.85%	Target Price	0.75	Perf Year	-99.00%
Cash/sh	0.05	P/C	1.00	EPS next 5Y	-	ROE	-524.01%	52W Range	0.06 - 6.09	Perf YTD	-98.95%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-205.49%	52W High	-99.13%	Beta	1.08
Dividend %	-	Quick Ratio	2.11	Sales past 5Y	27.11%	Gross Margin	5.51%	52W Low	-9.71%	ATR	0.01
Employees	20	Current Ratio	2.11	Sales Q/Q	-98.42%	Oper. Margin	-1268.76%	RSI (14)	27.19	Volatility	10.04% 10.21%
Optionable	No	Debt/Eq	0.14	EPS Q/Q	-132.97%	Profit Margin	-1475.02%	Rel Volume	0.20	Prev Close	0.06
Shortable	Yes	LT Debt/Eq	0.10	Earnings	Nov 09 BMO	Payout	-	Avg Volume	75.91M	Price	0.05
Recom	3.00	SMA20	-35.90%	SMA50	-51.18%	SMA200	-95.80%	Volume	14,997,372	Change	-12.54%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-21	Initiated	RBC Capital Mkts	Outperform	$6

Dec-07-23 07:00AM	Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split (GlobeNewswire) -5.61%
Nov-09-23 07:00AM	Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -10.09%
Oct-31-23 07:00AM	Avalo Completes Divestiture of AVTX-800 Series (GlobeNewswire) +18.00%
Sep-27-23 08:00AM	BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics (News Direct) +12.19%
Sep-26-23 07:00AM	Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation (GlobeNewswire) -7.36%
07:00AM	Loading…
Sep-12-23 07:00AM	Avalo Enters into Agreement to Divest AVTX-800 Series (GlobeNewswire) +45.47%
Sep-06-23 07:00AM	Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 07:00AM	Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-06-23 04:01PM	Avalo to Participate in SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-26-23 07:00AM	Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma (GlobeNewswire) -88.69%
Jun-01-23 07:00AM	Avalo to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-22-23 07:00AM	Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board (GlobeNewswire) -11.76%
May-15-23 07:00AM	Avalo to Present at ATS 2023 Respiratory Innovation Summit (GlobeNewswire) +11.79%
May-10-23 07:00AM	Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-04-23 04:01PM	Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -5.37%
07:30AM	Loading…
Mar-29-23 07:30AM	Avalo Reports 2022 Financial Results and Provides Business Updates (GlobeNewswire) -7.47%
Mar-07-23 07:00AM	Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-02-23 09:54PM	Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants (GlobeNewswire)
04:01PM	Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
Jan-17-23 07:00AM	Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma (GlobeNewswire)
Nov-07-22 07:30AM	Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million (GlobeNewswire)
Sep-06-22 07:00AM	Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage (GlobeNewswire) +22.29%
Sep-01-22 07:00AM	Avalo to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-11-22 04:01PM	Avalo Therapeutics Announces Board Changes (GlobeNewswire)
Aug-09-22 10:39AM	These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer (TipRanks) +32.14%
Aug-04-22 07:30AM	Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +10.96%
Aug-02-22 07:30AM	Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) (GlobeNewswire)
Aug-01-22 07:00AM	Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics (GlobeNewswire)
Jul-06-22 04:05PM	Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split (GlobeNewswire)
12:10PM	Loading…
Jun-20-22 12:10PM	Investors in Avalo Therapeutics (NASDAQ:AVTX) have unfortunately lost 90% over the last three years (Simply Wall St.)
Jun-02-22 07:30AM	Avalo to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-18-22 07:30AM	Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA) (GlobeNewswire) +6.82%
May-17-22 07:30AM	Avalo to Present at the H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) +15.08%
May-05-22 07:30AM	Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -16.27%
Mar-08-22 07:00AM	Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference (GlobeNewswire)
Mar-02-22 07:30AM	Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-17-22 07:30AM	Avalo Therapeutics Announces Leadership Transition (GlobeNewswire) -8.46%
Feb-07-22 04:01PM	Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference (GlobeNewswire)
Jan-10-22 07:59PM	Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer (GlobeNewswire) -6.20%
Jan-06-22 07:30AM	Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event (GlobeNewswire) -31.25%
Dec-16-21 07:30AM	Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022 (GlobeNewswire)
Dec-06-21 07:30AM	Avalo Appoints Two New Independent Directors to Its Board (GlobeNewswire)
Dec-05-21 06:43AM	What Type Of Shareholders Make Up Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) Share Registry? (Simply Wall St.)
Nov-11-21 07:00AM	Avalo to Present at Two Upcoming Conferences (GlobeNewswire)
Nov-09-21 04:01PM	Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-13-21 07:00AM	Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit (GlobeNewswire)
Oct-06-21 04:15PM	Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update (PR Newswire)
Sep-20-21 07:00AM	Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire) -5.91%
Sep-17-21 09:11AM	Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares (GlobeNewswire) +9.48%
Sep-14-21 10:23PM	Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock (GlobeNewswire)
04:01PM	Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Sep-06-21 06:43AM	Avalo Therapeutics' (NASDAQ:AVTX) investors will be pleased with their favorable 35% return over the last year (Simply Wall St.)

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARMISTICE CAPITAL, LLC	10% Owner	Jun 27	Sale	0.52	937,404	486,888	731,458	Jun 28 06:12 PM
ARMISTICE CAPITAL, LLC	10% Owner	Jun 26	Sale	0.61	2,746,138	1,682,010	1,668,862	Jun 28 06:12 PM
Caissa Capital Management ltd.	10% Owner	Jun 20	Buy	4.14	2,000	8,289	1,425,700	Jun 20 04:04 PM
Caissa Capital Management ltd.	10% Owner	Jun 16	Buy	3.90	3,000	11,714	1,423,700	Jun 20 04:04 PM
Caissa Capital Management ltd.	10% Owner	Jun 15	Buy	3.68	3,160	11,640	1,420,700	Jun 20 04:04 PM
Caissa Capital Management ltd.	10% Owner	Jun 14	Buy	3.48	6,000	20,874	1,417,540	Jun 14 04:14 PM
Caissa Capital Management ltd.	10% Owner	Jun 13	Buy	3.82	8,750	33,439	1,411,540	Jun 14 04:14 PM
Caissa Capital Management ltd.	10% Owner	Jun 12	Buy	4.34	2,149	9,316	1,402,790	Jun 14 04:14 PM
Caissa Capital Management ltd.	10% Owner	Jun 09	Buy	4.14	5,044	20,896	1,400,641	Jun 09 04:24 PM
NEIL GARRY ARTHUR	CEO and Chairman of the Board	Jun 09	Buy	3.42	4,000	13,680	13,220	Jun 13 04:39 PM
Sullivan Christopher Ryan	Chief Financial Officer	Jun 09	Buy	3.42	511	1,748	1,262	Jun 13 04:41 PM
Caissa Capital Management ltd.	10% Owner	Jun 08	Buy	3.93	6,398	25,126	1,395,597	Jun 09 04:24 PM
Caissa Capital Management ltd.	10% Owner	Jun 07	Buy	3.49	2,984	10,418	1,389,199	Jun 09 04:24 PM
Caissa Capital Management ltd.	10% Owner	May 31	Buy	2.87	844	2,422	1,386,215	Jun 02 04:22 PM
Caissa Capital Management ltd.	10% Owner	May 30	Buy	2.87	671	1,924	1,385,371	May 30 04:27 PM
Caissa Capital Management ltd.	10% Owner	May 25	Buy	2.77	2,000	5,540	1,384,700	May 30 04:27 PM
Caissa Capital Management ltd.	10% Owner	May 24	Buy	2.98	9,000	26,816	1,382,700	May 24 04:15 PM
Caissa Capital Management ltd.	10% Owner	May 22	Buy	3.34	7,000	23,358	1,373,700	May 22 04:30 PM
Caissa Capital Management ltd.	10% Owner	May 19	Buy	3.52	6,500	22,852	1,366,700	May 22 04:30 PM
Caissa Capital Management ltd.	10% Owner	May 18	Buy	3.29	13,121	43,163	1,360,200	May 22 04:30 PM
Caissa Capital Management ltd.	10% Owner	May 16	Buy	2.75	379	1,042	1,347,079	May 16 05:23 PM
Caissa Capital Management ltd.	10% Owner	May 15	Buy	2.55	1,715	4,366	1,346,700	May 16 05:23 PM
Caissa Capital Management ltd.	10% Owner	May 12	Buy	2.45	2,285	5,598	1,344,985	May 16 05:23 PM
Caissa Capital Management ltd.	10% Owner	May 08	Buy	2.62	5,000	13,108	1,342,700	May 08 04:10 PM
Caissa Capital Management ltd.	10% Owner	May 05	Buy	2.88	5,000	14,375	1,337,700	May 08 04:10 PM
Caissa Capital Management ltd.	10% Owner	May 04	Buy	2.79	15,000	41,882	1,332,700	May 08 04:10 PM
Caissa Capital Management ltd.	10% Owner	Apr 27	Buy	2.96	1,504	4,452	1,317,700	Apr 27 04:07 PM
Caissa Capital Management ltd.	10% Owner	Apr 26	Buy	2.97	425	1,262	1,316,196	Apr 27 04:07 PM
Caissa Capital Management ltd.	10% Owner	Apr 25	Buy	3.00	5,571	16,709	1,315,771	Apr 27 04:07 PM
Caissa Capital Management ltd.	10% Owner	Apr 24	Buy	3.06	12,500	38,280	1,310,200	Apr 24 04:32 PM
Caissa Capital Management ltd.	10% Owner	Apr 20	Buy	3.08	5,000	15,392	1,297,700	Apr 24 04:32 PM
Caissa Capital Management ltd.	10% Owner	Apr 18	Buy	2.94	10,000	29,438	1,292,700	Apr 18 04:08 PM
Caissa Capital Management ltd.	10% Owner	Apr 17	Buy	2.96	15,000	44,436	1,282,700	Apr 18 04:08 PM
Caissa Capital Management ltd.	10% Owner	Apr 11	Buy	2.84	25,000	71,080	1,267,700	Apr 11 04:51 PM
Caissa Capital Management ltd.	10% Owner	Apr 10	Buy	2.28	31,329	71,436	1,242,700	Apr 11 04:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVTX

Avalo Therapeutics Inc

Upgrade your FINVIZ experience